Real‐World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study

Background and Aim: Quality of life (QoL) of psoriasis patients treated with calcipotriol/betamethasone dipropionate (Cal/BD) foam has not been thoroughly evaluated in real‐world settings. This study evaluated the change in plaque psoriasis patients’ QoL after 4 weeks of first treatment with Cal/BD foam and after 6 months under daily practice conditions. Methods: A prospective, noninterventional study evaluated QoL, treatment adherence, satisfaction, and efficacy through the dermatology life quality index (DLQI), the Morisky‐Green scale, the treatment satisfaction questionnaire for medication (TSQM‐9), and the change in the body surface area (BSA) with plaque psoriasis, among others. Results: A total of 172 adult patients with plaque psoriasis were included. After 4 weeks of treatment, 53.5% of patients had a DLQI score ≤ 1. Mean absolute change in the DLQI score from baseline was −4.2 after 4 weeks of treatment and −4.0 after the 6‐month follow‐up ( p < 0.0001). Improvement in the BSA was statistically significant after the first treatment period and after the 6‐month follow‐up with a mean reduction of 2.4% and 2.6%, respectively ( p < 0.0001). Mean absolute change in global satisfaction between the end of the 4‐week treatment period and the 6‐month follow‐up was −4.3 ( p = 0.0049). In total, 41% of patients were compliant after the first treatment period, and 55.3% were moderately compliant. Higher patient treatment satisfaction was moderately correlated with lower DLQI scores after 4 weeks ( r = −0.527; p < 0.0001). Statistically significant differences between DLQI groups were found in the BSA: patients with DLQI ≤ 1 after 4 weeks of treatment had a lower BSA than patients with DLQI > 1 (1.3 ± 1.8 vs. 2.8 ± 2.7, respectively; p < 0.0001). Conclusion: After 4 weeks of treatment, daily use of Cal/BD foam in plaque psoriasis patients resulted in an improvement in QoL that was related to an improvement in both satisfaction and efficacy.